PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
91.74%
Some net income increase while GNPX is negative at -17.92%. John Neff would see a short-term edge over the struggling competitor.
-100.00%
Negative yoy D&A while GNPX is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
100.00%
Deferred tax of 100.00% while GNPX is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-95.76%
Both cut yoy SBC, with GNPX at -51.17%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-167.13%
Negative yoy working capital usage while GNPX is 193.21%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-230.77%
Both negative yoy AP, with GNPX at -231.79%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-79.38%
Negative yoy usage while GNPX is 214.13%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-151.83%
Negative yoy while GNPX is 0.00%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
55.51%
Operating cash flow growth above 1.5x GNPX's 7.14%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
52.86%
CapEx growth of 52.86% while GNPX is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.86%
We expand invests by 52.86% while GNPX is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.